Assessing the performance of alternative methods for estimating long-term survival benefit of immuno-oncology therapies

To determine the accuracy and consistency of established methods of extrapolating mean survival for immuno-oncology (IO) therapies, the extent of any systematic biases in estimating long-term clinical benefit, what influences the magnitude of any bias, and the potential implications for health technology assessment (HTA).
Source: Value in Health - Category: International Medicine & Public Health Authors: Tags: Methodology Source Type: research